drugset / Trial / NCT01470209
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the safety of combining two agents (everolimus and BKM120) for the treatment of advanced cancer arising from solid organ in patients who are no longer benefiting from or unable to withstand standard treatment of these conditions.
Timeline
- Start
- 2012-01
- Primary completion
- 2017-05
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buparlisib | Small molecule | 20 mg | Oral |
| Subject | Buparlisib | Small molecule | 100 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |